InfuSystem Holdings Inc Dossier - Source-backed chat

InfuSystem Holdings Inc

INFUNYSE

SectorHealth Care

IndustryHealth Care Services

Beta (adjusted)1.31

Intrinsic Value $9.32median of 5 methods · middle span $9-$10based on filings through 30 Jun 2026

Market Price $12.82Price as of 1 Oct 2026

OvervaluedIntrinsic value is 27% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $255.3M

Enterprise Value $274.8M

Shares Outstanding 20.7M diluted

Moat Rating Narrow

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

InfuSystem Holdings, Inc. (INFU) is undergoing a transition from a high-volume, lower-margin biomedical services model to a higher-margin, specialized clinical services provider. While the strategic restructuring of its GE HealthCare contract creates a near-term top-line headwind of $7.1 million (approximately 5.5% of revenue), it significantly improves gross and operating margins. Growth is increasingly driven by high-margin therapies, particularly Wound Care (which grew 112% YoY in Q1 2026 to represent 6% of total revenue) and Pain Management, supported by regulatory tailwinds like the NOPAIN Act. With the successful go-live of its new ERP system in March 2026, capital expenditures are tapering down, positioning the company for substantial free cash flow generation and margin expansion in 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$14.88

High · most bullish analyst$17.50

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The transition of the oncology RCM to the Apollo platform experiences operational delays, disrupting billing cycles. Competitive pressures in the home-based care and medtech space from larger players limit market share gains in Wound Care. Additionally, persistent ERP-related expenses or failure to realize the expected margin improvements from the restructured GE HealthCare contract keeps Adjusted EBITDA margins below 20%.

Base CaseCentral scenario

The unaffected core business achieves pro-forma net revenue growth of 6% to 8% in 2026. The strategic shift toward Patient Services (Oncology and Wound Care) successfully offsets the Device Solutions decline from the GE HealthCare contract restructuring. Adjusted EBITDA margins expand into the low-to-mid 20% range as ERP implementation costs taper off in the second half of 2026, and the company leverages its strong operating cash flow to continue its share buyback program.

Bull CaseUpside scenario

Strong free cash flow generation, margin expansion driven by the high-margin Patient Services segment (Oncology and Wound Care), and operational efficiencies from the newly implemented ERP system.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High-margin Patient Services segment (Oncology and Wound Care) continues to show robust organic growth, up 6.4% in Q1 2026.
Wound Care revenue more than doubled year-over-year, driven by strategic partnerships and the Apollo Medical Supply acquisition.
Restructuring of the GE HealthCare contract improves Device Solutions gross margin by 7.2% despite lower segment revenue.
Strong liquidity profile with $2.1 million in cash and $55 million available on its revolving credit facility, supported by active share repurchases.

Key Investment Risks

High concentration of revenue within the oncology business (representing approximately 87% of Patient Services revenue).
Vulnerability to changes in third-party payer coverage policies and reimbursement rates.
Execution risks associated with the ongoing migration of oncology RCM to the Apollo platform.
Intense competition from larger, well-capitalized healthcare service and distribution players.

Thesis Invalidation Triggers

Adjusted EBITDA margins failing to reach the projected low-to-mid 20% range by late 2026.
A significant decline in oncology treatment volumes or loss of key oncology clinic relationships.
Failure of Wound Care growth to sustain double-digit momentum, indicating a lack of market adoption for new partnerships.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.